Electro-Acupuncture plus PD-1 inhibitors and chemotherapy in advanced NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized study compares electro-acupuncture with sham acupuncture when given alongside standard first-line chemotherapy and a PD-1 inhibitor for advanced non-small cell lung cancer lacking actionable mutations. Participants are randomized 1:1 to receive either the electro-acupuncture or a sham control during 4 to 6 cycles of induction therapy. The primary endpoint is progression-free survival, with secondary endpoints including overall survival, objective response rate, disease control rate, duration of response, and patient-reported quality of life and symptom burden. Safety will be monitored by adverse events graded per standard criteria. The trial plans to enroll 424 patients across multiple centers in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.
2. Tumor proportion score for PD-L1 \< 50%.
3. Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).
4. No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (induction) treatment with ICIs plus chemotherapy are eligible. Patients who have received prior neoadjuvant or adjuvant therapy, or definitive chemoradiotherapy, may be enrolled if provided that disease progression occurred more than 6 months after the completion of the last treatment.
5. ECOG performance status score of 0-2.
6. Age ≥ 18 years.
7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
8. Adequate organ function (hematology: ANC ≥ 1500/mcL, PLT ≥ 100,000/mcL, Hb ≥ 9.0 g/dL or ≥ 5.6 mmol/L; renal function: estimated creatinine clearance ≥ 50 mL/min; hepatic function: serum total bilirubin ≤ 1.5 × ULN or total bilirubin \> 1.5 × ULN with direct bilirubin ≤ ULN, AST and ALT ≤ 2.5 × ULN ≤ 5 × ULN for patients with liver metastases).
9. Voluntary participation in the study, signed informed consent form, good compliance, and cooperation with follow-up.

Exclusion Criteria:

1. Inability to complete baseline assessments.
2. Pregnant or lactating women, and those with psychiatric, intellectual, or language disorders.
3. Patients with autoimmune diseases or hematologic disorders requiring long-term use of hormones or immunosuppressants.
4. Presence of concurrent primary malignant tumors at other sites.
5. Participation in another investigational drug or device clinical trial within 30 days prior to the planned initiation of study treatment.
6. Known seropositivity for human immunodeficiency virus (HIV), other congenital or acquired immunodeficiencies, or history of organ or stem cell transplantation (including autologous bone marrow or peripheral blood stem cell transplantation).
7. Loss of self-care capacity, or any medical, psychological, or ethical condition that, in the investigator's judgment, could interfere with the patient's ability to complete the study.
8. Active skin infection, ulceration, or lesion at acupuncture point sites that would preclude safe administration of treatment.
9. Implanted cardiac pacemaker or other active implantable electronic medical device.
10. Severe needle phobia that would prevent acceptance of needling procedures required by the study protocol.
11. Receipt of any acupuncture or related needle-based therapy within 6 weeks prior to enrollment.
12. Active pneumonitis, or radiation pneumonitis requiring treatment with systemic corticosteroids.
13. Active infection requiring antimicrobial therapy (antibacterial, antifungal, or antiviral agents) according to clinical guidelines at the time of screening. Enrollment may be reconsidered after the infection has been adequately controlled.
14. Active tuberculosis infection, or any severe or uncontrolled systemic illness, including but not limited to clinically significant neurological conditions (e.g., uncontrolled seizures, dementia), unstable or decompensated respiratory, cardiac, hepatic, or renal disease.

Where it's running

• Guangdong Provincial Hospital of Chinese Medicine
  Guangzhou, Guangdong, China Recruiting
• The First Affiliated Hospital of Guangzhou University of Chinese Medicine
  Guangzhou, Guangdong, China Recruiting
• Jiangsu Provincial Hospital of Chinese Medicine
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Haibo Zhang — Guangdong Provincial Hospital of Traditional Chinese Medicine
• Study coordinator: Yanjuan Zhu, MD
• Email: zyjsophy@gzucm.edu.cn
• Phone: 86 20 81887233

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2

  This trial will see if adding electroacupuncture to PD‑1 immunotherapy helps people with advanced non‑small cell lung cancer who have an ECOG performance status of 2.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07239661

• Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer

  It will test whether adding electroacupuncture to PD‑1 immunotherapy helps people aged 65 and older with advanced non‑small cell lung cancer live longer, feel better, or have fewer side effects.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07086300

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.